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Abstract
Chromothripsis is a one-step genome-shattering catastrophe resulting from disruption of one or few chromosomes in
multiple fragments and consequent random rejoining and repair. This study defines incidence of chromothripsis in 395
newly diagnosed adult acute myeloid leukemia (AML) patients from three institutions, its impact on survival and its genomic
background. SNP 6.0 or CytoscanHD Array (Affymetrix®) were performed on all samples. We detected chromothripsis with
a custom algorithm in 26/395 patients. Patients harboring chromothripsis had higher age (p= 0.002), ELN high risk (HR) (p
< 0.001), lower white blood cell (WBC) count (p= 0.040), TP53 loss, and/or mutations (p< 0.001) while FLT3 (p= 0.025),
and NPM1 (p= 0.032) mutations were mutually exclusive with chromothripsis. Chromothripsis-positive patients showed a
worse overall survival (OS) (p< 0.001) compared with HR patients (p= 0.011) and a poor prognosis in a COX-HR optimal
regression model. Chromothripsis presented the hallmarks of chromosome instability [i.e., TP53 alteration, 5q deletion,
higher mean of copy number alteration (CNA), complex karyotype, alterations in DNA repair, and cell cycle] and focal
deletions on chromosomes 4, 7, 12, 16, and 17. CBA. FISH showed that chromothripsis is associated with marker,
derivative, and ring chromosomes. In conclusion, chromothripsis frequently occurs in AML (6.6%) and influences patient
prognosis and disease biology.
Introduction
Loss of chromosomes and complex karyotype are
mechanisms of genomic instability known to be linked to
therapy resistance, poor prognosis, and early relapse in
AML [1–3]. Nowadays, new high-throughput technologies
can discover new alterations responsible for the poor
prognosis in subcohorts of AML patients and may reveal
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druggable pathways. There is an urgent need to define
genomic phenotypes in AML in a therapeutic perspective.
Chromothripsis is a one-step genomic catastrophe
involving one or few chromosomes resulting from chro-
mosome breakage and random DNA rejoining [4]. It has
been detected, mainly as occasional finding, in solid tumors
[5–13] and hematological malignancies (multiple myeloma
[14], AML [15, 16], acute lymphoblastic leukemia [17, 18],
and chronic lymphocytic leukemia [19]), as well as in
germline cases of congenital disorders [20]. A study on
22,000 cases of primary tumors highlighted an overall
incidence of chromothripsis between 2 and 3% [21].
During mitosis, chromothripsis arises from aberrant
DNA replication timing. Prolonged arrest of cell cycle and
micronuclei formation influence the spatial distribution of
damages favoring the acquisition of structural rearrange-
ments [22]. Molecular mechanisms implicated in this event
are only partially discovered. Chaotic genomes seemed to
form through random non-homologous end joining after
DNA damages [23]. An alternative theory presented chro-
mothripsis as a putative incomplete outcome of chromo-
some fragmentation, the initial event triggering a new form
of mitotic cell death [23]. Moreover, recent evidence indi-
cates that chromothripsis preferentially occurs especially in
hyperploid cells [24] and in cells with damaged telomeres
[25]. Chromothripsis has been associated to EGFR, MDM2,
and MDM4 amplification, CDKN2A and PTEN deletion [8],
aberrant DNA double-strand break (DSB) response [26],
TP53 mutations [9, 15], complex karyotype [9, 15], and
ATM mutation [18].
At present, a standardized way to detect chromothripsis
does not exist, but few have been proposed. Chromothripsis
has been identified with fluorescent in situ hybridization
(FISH) [9, 15, 16, 26], or, alternatively, by operator-
dependent analyses [14] as well as algorithm-based detec-
tion of shattering patterns on SNP array data and eventual
integration with DNA sequencing data [21, 27]. Korbel and
Campbell defined six different criteria to distinguish chro-
mothripsis from a multi-step process of genomic rearran-
gement [28]. When analyzed by SNP arrays, chromosomes
harboring chromothripsis show a characteristic pattern of
alterations: two or three switches of CN state detectable
along the chromosome with a clustering of breakpoint
locations [29]. These patterns are associated with a high
number of chromosomal rearrangements with widespread
loss or gain of sequence fragments interspersed in diploid
regions [21].
Chromothripsis has been associated with highly aggres-
sive disease in various tumors [8–14] but it did not appear to
impact prognosis in prostate cancer [30] and in estrogen
receptor-negative breast cancer [12].
Our study describes the incidence of chromothripsis at
diagnosis in a large and homogenous AML cohort, its




Samples and data at diagnosis from 395 adult patients
affected by de novo or secondary AML according to WHO
2016 criteria [31] were collected from three institutions. The
study was approved by the local ethical committees, written
permission, and informed consent were obtained from all
patients before sample collection according to Helsinki
declaration of “Ethical Principles for Medical Research
Involving Human Subjects” [32].
Data were collected and managed through custom
Electronic Case Report Forms using REDCap electronic
data capture tool [33].
SNP microarray analysis
DNA samples were processed by Affymetrix® (Santa
Clara, CA, USA) genome-wide human SNP 6.0 (n= 321)
and CytoscanHD Array (n= 84) according to the manu-
facturer’s instructions. Of the 114 SNP 6.0 AML cases
obtained from GSE23452, 112 were paired samples,
including buccal swab DNA or bone marrow at remission




Chromothripsis was defined according to Korbel and
Campbell’s criteria [28], when three out of six criteria were
satisfied (the remaining criteria could not be assessed by
SNP array analysis).
Chromothripsis was assessed by scanning SNP array
segment files using CTLP-Scanner (using R v3.3.2 [35] and
“CTLP scanner” package [21]). The following thresholds
were set: Log ratio ≥8, more than 10 breakpoints, minimum
segment size of 10 kb, and 0.3 as signal distance between
adjacent segments. Events with a prevalent copy number
(CN) status and changes involving ≤10% of detected region
were excluded.
Microarray statistical analyses
Based on the presence/absence of chromothripsis, AML
samples were divided in two groups: a group of cases
(chromothripsis-positive) and a group of controls (chro-
mothripsis-negative) and enrichment of CNA events
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between the two groups was examined. The data set was
stratified for event type and the statistical tests were per-
formed on amplifications of one or more DNA copies and
heterozygous or homozygous deletions. In each patient,
multiple events of the same type in the same gene were
considered as one. Fisher’s exact test was used to compare
frequencies in genes’ event between two groups. All p
values were adjusted for multiple testing. For testing at a
pathway level, genes were annotated in the Reactome
database [36]. Pathway enrichment analysis was performed
at patient level by means of an over-representation test.
Then, the adjusted p values obtained for a certain pathway
across all patients were used as predictor variable in a
logistic regression model. The significance level was set at
10–4.
Chromosome banding analysis and FISH
FISH analysis was carried out on previously G-banded
metaphases prepared by chromosome banding analysis
(CBA) technique according to the manufacturer’s
instructions.
Clinical statistical analysis
Due to the data-pool feature of our set, missing data will be
detailed in the result section. OS was assessed as the time in
days from diagnosis to death or last follow-up.
Fisher’s exact test and chi-squared test were used for
crosstabs and difference between distributions was assessed
with median test for independent samples and
Mann–Whitney U test. Survival analysis and COX-HR
were used as appropriate.
Results
Clinical and molecular patient characteristics
All patients' clinical and molecular characteristics are listed
in Table 1, missing data are quantified in Table S1. In our
cohort, 26 out of 395 patients (6.6%) showed chromo-
thripsis involving different chromosomes.
Correlation of chromothripsis with clinical and
molecular parameters in AML patients
We compared chromothripsis-negative patients with
chromothripsis-positive ones (Table 2). Chromothripsis-
positive patients were older. They had a higher median age
(67 and 60 years, respectively p= 0.002, Figure S1C) and a
lower WBC count mean at diagnosis (6342/mm3 vs. 30,059/
mm3, respectively p= 0.040, Figure S1A). Chromothripsis-
positive patients presented a prevalence of complex kar-
yotype and were classified as HR disease according to ELN
[37] definition (p< 0.001, Figure S1D).
Based on genetic features, chromothripsis was associated
with TP53 loss (p< 0.001) and TP53 mutations (p< 0.001).
Table 1 Clinical and molecular characteristics of the patients enrolled
in this study (N= 395)
Parameter Value
Age Median 59.35 (range,
16–92)
Sex 185/395 patients were
female (46.8%)
210/395 patients were male
(53.2%)
De novo AML 307/372 patients (82.5%)
AML secondary to myelodysplastic
syndrome
43/372 patients (11.6%)
AML secondary to other myeloid
neoplasms
4/372 patients (1.1%)
Therapy-related AML 18/372 patients (4.8%)
WBC (mean) 28.140/mm3 (100–171.00/
mm3)
WBC count greater than 30,000/mm3 46/154 patients (29.9%)
WBC count greater than 100,000/mm3 12/154 patients (7.8%)




intermediate 1 risk [37]
100/352 patients (28.4%)
European LeukemiaNet (ELN)
intermediate 2 risk [37]
80/352 patients (22.7%)
European LeukemiaNet (ELN) high
risk [37]
137/352 patients (38.9%)




Complete remission 153/251 patients (60.9%)
Hematopoietic stem cell transplant 85/283 patients (30.0%)
Loss or a mutation of TP53 at
diagnosis
63/395 patients (15.9%)
Loss 29/395 patients (7.3%)
Mutation 53/324 patients (16.4%)
Internal tandem duplication in FLT3 42/298 patients (14.1%)
Tyrosine kinase domain mutation in
FLT3
18/298 patients (6.0%)
Mutations in NPM1 gene 50/286 patients (17.5%)
Mutations in IDH1 gene 4/121 patients (3.3%)
Mutations in IDH2 gene 11/135 patients (8.3%)
Mutations in DNMT3A gene 7/38 patients (19.4%)
Mutations in CEBPA gene 5/106 patients (4.7%)
Mutations in RUNX1 gene 11/87 patients (12.6%)
Mutations in CBL gene 2/91 patients (2.2%)
Mutations in NRAS gene 10/95 patients (10.5%)
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Only 3/26 patients did not harbor any TP53 alteration: one
patient was TP53 wild-type and have no karyotype aber-
ration involving 17p, two patients were not tested for TP53
mutation because of unavailable material at diagnosis.
Chromothripsis was mutually exclusive with FLT3 (Figure
S1B, p= 0.025) and NPM1 mutations (p= 0.032).
Chromothripsis defined a group of AML patients
with poor response to induction therapy
At diagnosis, patients received chemotherapy, hypomethy-
lating agents, or best supportive therapy (Table 3). Patients
with chromothripsis were treated with intensive che-
motherapy in a smaller proportion (p= 0.003). There was
no difference in use of Gemtuzumab Ozagomicin during
induction between the two group of patients (p= 1.000) and
there was a similar transplant rate between the two groups
[21% of patients with chromothripsis and 31% of patients
without chromothripsis received hematopoietic stem cell
transplant (HSCT), p= 0.448].
Chromothripsis defined a group of patients with poor
prognosis. Three out of 10 patients with chromothripsis
(30%) responded to induction, a significant lower propor-
tion if compared with 152/229 patients without chromo-
thripsis (66.4%, p= 0.036).
Chromothripsis defined a group of AML patients
with poor OS
Patients with chromothripsis showed a worse OS (median
OS of 120 days compared to 494 days for patients without
chromothripsis, p< 0.001, Fig. 1a). In patients with avail-
able HSCT data, we confirmed the difference by censoring
OS at HSCT with a median OS of 120 and 400 days in the
two groups (p< 0.001, Fig. 1b). Patients with chromo-
thripsis had the worst prognosis among patients with HR
features according ELN [37] risk stratification (median OS
of 120 and 258 days in the two groups, p= 0.011, Fig. 1c).
This observation was confirmed when censoring OS at
HSCT (median OS of 120 and 211 days in the two groups,
p= 0.022, Fig. 1d). Moreover, the impact of chromothripsis
on OS was evaluated in patients with HR features according
ELN [37] risk stratification, who received induction
chemotherapy. We report a difference in survival between
patients with and without chromothripsis (median OS of
120 and 295 days, respectively, p= 0.040, Fig. 1e) and a
trend toward statistical significance in HSCT-censored
analysis (median OS of 120 and 242 days, respectively, p
= 0.055, Fig. 1f). Patients with chromothripsis did not show
differences in baseline characteristics or in survival com-
pared to patients harboring TP53 mutation, TP53 loss, or to
the group of patients harboring TP53 alteration (loss and/or
mutation), due to the high co-occurrence of these two
phenomena (Figure S2 and Table S2). However, in our set,
patients with chromothripsis showed a survival dis-
advantage near to the statistical significance threshold when
compared with patients with TP53 loss (Fig. S2B, p=
0.049).
Chromothripsis was an independent predictor of
shorter OS in COX-HR model
We built a prognostic model using COX-HR with forward
conditional method, considering chromothripsis event,
secondary AML, ELN risk, induction therapy, FLT3 and
NPM1 mutation as categorical variables and age at diag-
nosis. TP53 status was not included in the model for the
high co-occurrence of chromothripsis and TP53 alterations.
In the optimal model, chromothripsis (HR: 2.286, 95% CI:
1.327–3.940, p= 0.003) and secondary disease was asso-
ciated with augmented risk of death, while ELN low risk,
intermediate 1 and intermediate 2 risk were associated with
better outcome (Fig. 2). Chromothripsis was a consistent
risk factor in COX-HR model built in ELN HR population
considering chromothripsis, secondary AML, induction
therapy, FLT3 mutation, and NPM1 mutation as categorical
variables, and age of diagnosis (HR: 2.070, 95% CI:
1.167–3.672, p= 0.013, model not shown). Chromothripsis
was also a consistent risk factor in COX-HR model built in
ELN HR population treated with intensive therapies con-
sidering chromothripsis, secondary AML, FLT3 mutation,
and NPM1 mutation as categorical variables, and age of
diagnosis (HR: 2.227, 95% CI: 1.022–4.850, p= 0.044,
model not shown).
Genomic characteristics of AML patients with
chromothripsis
We detected chromothripsis on chromosome 12 (23% of
events), 17 and 5 (17% of events both), chromosomes 6
(10% of events), 3 and 8 (6.6% of events both), 7, 10, 11,
15, and 20 (3.3% of events each) (Fig. 3, and Fig. S3). SNP
array analyses showed that chromothripsis-positive patients
were characterized by a high grade of genomic aberrations.
We found a minimal common-deleted region in 24/26
patients with chromothripsis (5q31.1–5q33.1). Among
Table 3 Induction therapies in patients with and without
chromothripsis
Induction therapy Chromothripsis
No (288) Yes (20)
Chemotherapy—n. 241 10
Hypomethylating agents—n. 23 4
Best supportive therapy—n. 24 6
Chromothripsis in acute myeloid leukemia 1613
Fig. 1 Association between chromothripsis and OS in AML. OS in
patients with (green line) and without chromothripsis (blue line): a
overall cohort; b survival censored at HSCT; c patients with ELN [37]
HR features; d patients with ELN [37] HR features censoring survival
at HSCT; e patients treated with intensive chemotherapy with ELN
2017h features; f patients treated with intensive chemotherapy with
ELN [37] HR features censoring survival at HSCT
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chromothripsis-negative patients, 51/369 harbored at least a
CNA of 9Mb in the 5q arm. There was a higher incidence
in macroscopic deletions on 5q in patients with chromo-
thripsis (p< 0.0001).
Patients with chromothripsis presented higher mean of
CNA than patients without chromothripsis (mean of 418 vs.
188 CNA per patient; Fig. 4, CIRCOS [38] external level).
Significative genomic alterations mapped in
relatively small chromosomic regions
Fisher's exact test showed that a large group of 1359 genes
were significantly altered in deletion (both heterozygous
and homozygous) in chromothripsis-positive patients rather
than chromothripsis-negative ones (data not shown). These
genes map on chromosome 5q, 3q, 12p, 3p, 4q, 7q, 12p,
16q, and 17p. Considering chromosome position of genes
associated with chromothripsis, we found that CNA ran-
domly affected the entire 5q and whole chromosome 3. In
the other chromosomes, we found that statistically sig-
nificant CNA mapped in relatively small regions (complete
list of genes in Fig. 4, CIRCOS [38] internal level). These
regions included deletions of genes involved in Atlas of
Genetics and Cytogenetics in Oncology and Haematology,
in particular on chromosome 4q28–32 (SFRP2),
7q31.1–36.3 (CAV1, EPHA1, and NRF1), 12p11.21–13.3
(EPS8, RECQL, and GUCY2C), 16q22–24.3 (transcription
factors CBFA2T3 and FOXF1; CDT1 involved in DNA
replication; and the Fanconi Anemia gene FANCA), and
17p13–13.1 (ALOX12 and CLDN7) (Fig. 4). Genes were
filtered as described in “Methods” and we showed that 95
genes were associated with chromothripsis (complete list of
genes in Fig. 4, CIRCOS [38] internal level).
Pathway enrichment in patients with
chromothripsis
REACTOME enrichment of pathways is reported in
Tables S3 and S4. DNA repair, E2F-mediated regulation of
DNA replication, signaling pathways involving PI3K,
phospholipid biosynthesis and metabolism, and various
growth factors signaling pathways scored in the best 1% of
pathways enriched for amplification events in chromo-
thripsis. CTLA4 inhibitory signaling, synthesis of phos-
phatidylinositol phosphate (PIP) at the late endosome
membrane, fanconi anemia pathway, genes regulating G0
and early G1 phase, pre-NOTCH transcription and transla-
tion scored in the best 1% of pathways enriched for deletion
events in cases with chromothripsis.
In the subcohort of patients with TP53 alteration, when
we compared patients with chromothripsis (n= 22) and
patients without chromothripsis (n= 44), we did not detect
any significant difference in terms of differentially altered
genes and pathways (with a significance threshold of p<
10–4).
Chromothripsis is associated with marker,
derivative, and ring chromosomes formation
In order to better characterize the chromosomes affected by
chromothripsis, we performed FISH analysis in 7/26 cases
with available material. Most cases (5/7) showed the
Fig. 2 COX-HR model. COX-HR model in patients’ set considering (a) forest plot of risk factors in COX-HR optimal model (b) in COX-HR
model, difference in OS (OS) representing population with (green line) and without (blue line) chromothripsis
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presence of marker or ring chromosomes. In four cases, the
chromosomes affected by chromothripsis (chromosomes 8,
11, 12, and 17) were reported by CBA as monosomic
chromosomes, while, by FISH, portions of these chromo-
somes were identified on marker chromosomes. In cases
involving chromosomes 8 and 11, the rearrangement led to
amplification of MYC and KMT2A (MLL) genes, respec-
tively. In cases involving chromosomes 12 and 17, parts of
the chromosomes affected by chromothripsis were identi-
fied on markers and on derivative chromosomes resulting
from unbalanced translocations. In other two cases, the
chromosome involved in chromothripsis was annotated as
derivative chromosome. Moreover, FISH highlighted the
presence of a homogeneously staining region on the deri-
vative chromosome 3 due to MDS1 and EVI1 complex
locus amplification in one case and of a complex translo-
cation involving chromosome 5 in the other case. In the last
patient, the chromosome affected by chromothripsis was
identified as ring chromosome 17 leading to loss of TP53.
FISH results are shown in Fig. 5.
Fig. 3 Representation of two chromosomes affected by chromothripsis
in different patients, plotted with Rawcopy v. 1.0. a Chromosome 17q
with 36 switches and 2–3 changes in CN (involving also homozygous
gains). b Chromosome 12p with 28 switches and 2–3 changes in CN
(involving also homozygous losses)
1616 M. C. Fontana et al.
Discussion
The purposes of this study was to define the incidence of
chromothripsis in newly diagnosed adult AML patients, its
impact on survival, and its genomic background in AML.
To detect chromothripsis, we used a custom algorithm
based on CTLP scanner [21] and Korbel and Campbell’s
criteria [28] that detected chromothripsis based on SNP
array data.
Our results, obtained in a large set of patients, indicate
that chromothripsis is a non-anecdotal finding in AML. The
overall incidence of chromothripsis was concordant with
studies conducted on fewer patients [15, 16]. Chromo-
thripsis appeared to be associated with higher age and lower
Fig. 4 CIRCOS plot representing the overall CNA and genes altered in
the two groups (chromothripsis-positive patients vs. chromothripsis-
negative patients). a External circular level: genomic landscape in
CNA per group of patients (external line represents chromothripsis-
positive patients, internal line represents chromothripsis-negative
patients). Green lines represent amplifications, red lines represent
deletions. b Internal list of selected genes (basing on Fisher's exact test
and Atlas of Genetics and Cytogenetics in Oncology and Haematol-
ogy) deleted in heterozygosis and/or homozygosis with relative fre-
quency in CNA displayed with histograms: chromothripsis-positive
patients (external level) and chromothripsis-negative patients (internal
level)
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WBC count at diagnosis, and mutually exclusive with FLT3
and NPM1 mutations, these data were never reported in
acute leukemia. Moreover, we confirmed the strong asso-
ciation between chromothripsis and TP53 dysregulation [9,
15], thus reinforcing the importance of TP53 for the
maintenance of genomic stability and integrity.
For the first time, we pointed out that the only detection
of chromothripsis is sufficient to define a group of patients
with poor prognosis in the general AML population and in
the ELN [37] high-risk population; chromothripsis was a
determinant of poor OS in the COX-HR optimal model. We
further performed survival analysis in the subset of patients
with TP53 alterations, as TP53 alone was reported to define
patients with the worst prognosis in AML [39–41]; we did
not detect differences in survival defined by to have or not
to have chromothripsis, and this was the main limitation of
our study. This may be explained by the low number of
patients in this subset, the moderate number of patients with
missing follow-up information, and by the slightly lower
mean OS of patients with TP53 alteration in our set when
compared with literature data [40]. Furthermore, we cannot
exclude that chromothripsis may be a phenotypical mani-
festation, or simply an epiphenomenon, of TP53 alteration.
Further tests are needed in patients’ sets enriched to have
TP53 alteration or to have chromothripsis without TP53
alteration.
Our work describes chromothripsis biological scenario
based on SNP high-throughput genomic analyses; even with
the limitations due to lack in availability of whole-genome
sequencing or gene expression data in our patients’ set, we
found several events significantly associated with chromo-
thripsis. Patients with chromothripsis presented a high
genomic instability, highlighted by the high number of
CNA per patient and a high recurrence of losses in chro-
mosome 3 and 5q and high incidence of complex kar-
yotype; this result is consistent with literature [9, 15, 18, 24,
25, 42–44].
Interestingly, we found in most patients with chromo-
thripsis a minimal common-deleted region in
5q31.1–5q33.1, containing key genes involved in RAS,
PI3K/AKT, transcriptional factors, DNA damage, histone
modification, and SMAD signaling. Moreover, we found
heterozygous and homozygous genes’ deletions associated
with chromothripsis that clustered in relatively small
genomic regions. Within altered genes, we hypothesized
that FANCA could be a candidate to cooperate at a multi-
genic and multi-step mechanism that initiate and maintain
chromothripsis. FANCA deletion is found in a relatively
small genome region; furthermore, it was found deleted in
sporadic AML [45] and it originate a syndrome that pre-
dispose to AML. Significantly, when we performed path-
way enrichment, we found DNA damage and fanconi
anemia pathways scoring within the best 1%, together with
Fig. 5 Karyotype analysis in AML patients harboring chromothripsis.
FISH analysis with a MYC breakapart probe showing five fusion
signals of MYC localized on normal chromosome 8 and on three
different marker chromosomes in patient with chromothripsis of
chromosome 8. b KMT2A (MLL) breakapart probe showing four
copies of KMT2A (four fusion signals) localized on the marker
chromosome resulted from chromothripsis of chromosome 11. c With
whole chromosome paint probe for chromosome 12 marked in blue
revealing part of chromosome 12 on the marker chromosome and on
the derivative chromosome 3 from translocation t (3;12). d Showing
deletion of TP53 gene (red signal) in the case with chromothripsis of
chromosome 17 annotated as ring chromosome by CBA
1618 M. C. Fontana et al.
early G0–G1 regulation, cell cycle, and several other
pathways that could be possibly related genesis and main-
tenance of chromothripsis. Tumors characterized by genetic
instability and by alterations in DNA damage pathway
could be the ideal target of innovative therapeutic approa-
ches like checkpoints inhibitors [46], and combination
therapies based on these agents could be an option in
chromothripsis patient for patients with poor prognosis.
Furthermore, our findings characterize a subset of AML
patients with a high burden of alterations and potentially
neoantigens that could be the optimal candidates for novel
therapies like PD1/PDL1 blocking monoclonal antibodies
and immune modulating drugs, maybe in combinations with
hypomethylating agents.
Compared to the subset of patients with TP53 alteration,
we did not find significant pathways and genes. This may be
due to the low number of patients in this subset, and it
requires further studies in enriched population with multi-
omics approach.
Finally, although only a subset of cases could be ana-
lyzed by CBA and FISH, our results showed that chromo-
thripsis was associated with marker, derivative, and ring
chromosomes, suggesting that these complex chromosomal
rearrangements can arise from chromothripsis. This finding
is in accordance with what Bochtler and colleagues pre-
viously reported [15].
In conclusion, chromothripsis is clearly a catastrophic
event defining a consistent group of patients with poor
prognosis, which could be candidate per se to novel
approaches; chromothripsis is associated with losses of
5q31.1–5q33.1 in most patients, and with a complex
genomic background in which FANCA, TP53, and genes
regulating cell cycle seem to be fundamental and demand
further preclinical studies.
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